<SEC-DOCUMENT>0001104659-20-072503.txt : 20200612
<SEC-HEADER>0001104659-20-072503.hdr.sgml : 20200612
<ACCEPTANCE-DATETIME>20200611175831
ACCESSION NUMBER:		0001104659-20-072503
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20200612
DATE AS OF CHANGE:		20200611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-235399
		FILM NUMBER:		20958224

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>tm2022403-1_s3a.htm
<DESCRIPTION>FORM S-3/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="#z_001">Table of Contents</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As filed with the Securities and
Exchange Commission on June 11, 2020</B> <B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Registration Statement No. 333-235399
</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
</B></FONT><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AMENDMENT
NO. 1 TO</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><BR>
FORM S-3<BR>
</B></FONT><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CELLDEX
THERAPEUTICS, INC.<BR>
</B></FONT>(Exact name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3191702</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State of Incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Perryville
III Building, 53 Frontage Road, Suite 220<BR>
Hampton, New Jersey 08827<BR>
(908) 200-7500<BR>
</B></FONT>(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Sam
Martin<BR>
Chief Financial Officer<BR>
CELLDEX THERAPEUTICS, INC.<BR>
Perryville III Building, 53 Frontage Road, Suite 220<BR>
Hampton, New Jersey 08827<BR>
(908) 200-7500<BR>
</B></FONT>(Name, address, including zip code and telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Anthony O. Pergola, Esq.<BR>
Lowenstein Sandler LLP<BR>
1251 Avenue of the Americas<BR>
New York, New York 10020<BR>
(212) 262-6700 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate date of commencement of proposed
sale to the public:<BR>
From time to time after this registration statement becomes effective, as determined by the registrant. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box: </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box: </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering. </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &quot;large accelerated filer,&quot; &quot;accelerated filer&quot;, &quot;smaller reporting company,&quot; and &quot;emerging
growth company&quot; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated<BR>
    filer: </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer: </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></FONT></TD>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer: </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></FONT></TD>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 20%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Smaller
                           reporting<BR>
                           company: </FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
        growth<BR>
        company: </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
</FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 2.5pt double; font-size: 10pt; text-align: center; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 2.5pt double; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 2.5pt double; font-size: 10pt; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price(1)(2)(3)</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 2.5pt double; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 2.5pt double; font-size: 10pt; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount of<BR>
Registration Fee(2)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 3pt; font-size: 10pt; text-indent: -3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 3pt; font-size: 10pt; text-indent: -3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 3pt; font-size: 10pt; text-indent: -3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 3pt; font-size: 10pt; text-indent: -3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depositary Shares</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 3pt; font-size: 10pt; text-indent: -3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units(4)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 2.5pt double; padding-left: 3pt; font-size: 10pt; text-indent: -3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150,000,000</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$19,470(5)</FONT></TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The amount to be registered and the proposed maximum
aggregate offering price per security are not specified as to each class of securities to be registered pursuant to General Instruction
II.D. of Form S-3 under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The securities covered by this
registration statement may be sold or otherwise distributed separately or together with any other securities covered by this registration
statement.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">(2)</TD><TD STYLE="text-align: justify">The registrant is hereby registering an indeterminate
amount of each identified class of securities up to a proposed maximum aggregate offering price of $150,000,000, which may be
offered from time to time in unspecified amounts at unspecified prices. The registrant has estimated the proposed maximum aggregate
offering price solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. Securities
registered hereunder may be sold separately, together or as units with other securities registered hereunder. The securities registered
hereunder include securities that may be purchased by underwriters to cover over-allotments, if any.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">(3)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities Act, this registration
statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend
or similar transaction. Includes consideration to be received by the registrant, if applicable, for registered securities that
are issuable upon exercise, conversion or exchange of other registered securities.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">(4)</TD><TD STYLE="text-align: justify">Consisting of some or all of the securities listed above,
in any combination, including common stock, preferred stock, warrants and depositary shares.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">(5)</TD><TD STYLE="text-align: justify">Pursuant to Rule 415(a)(6) under the Securities Act,
the securities registered pursuant to the registration statement include $147,459,779.61 of unsold securities previously registered
on the registrant's registration statement on Form S-3 filed on December 2, 2016 which was declared effective by the Securities
and Exchange Commission on February 13, 2017 (File No. 333-214882) (as amended, the &quot;Prior Registration Statement&quot;). The Prior Registration Statement
registered securities for a proposed maximum aggregate offering price of $250,000,000, of which $147,459,779.61 remain unsold.
In connection with the filing of the Prior Registration Statement, the registrant paid a registration fee of $17,090.59 in respect
of such unsold securities. In accordance with Question 212.24 of the Securities and Exchange Commission, Division of Corporation
Finance's Compliance and Disclosure Interpretations regarding Securities Act Rules, the registrant is not required to pay any additional
fee with respect to the $147,459,779.61 of unsold securities being included in this registration in reliance on Rule 415(a)(6),
because such unsold securities (and associated fees) are being moved from the Prior Registration Statement to this registration
statement. Accordingly, the registrant paid only the registration fee of $2,379.41 attributable to the $2,540,220.39 of new securities
registered on this registration statement. Pursuant to Rule 415(a)(6) of the Securities Act, the $17,090.59 registration fee previously
paid by the registrant relating to the unsold securities included on this registration statement will continue to be applied to
such unsold securities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this Registration Statement
on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ef505f"><B>The information in this prospectus is not
complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ef505f">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #ef505f"> <B>Subject to Completion,
dated June 11, 2020</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #ef505f">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2022403-1_s3aimg001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>CELLDEX
THERAPEUTICS, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>$150,000,000<BR>
Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Depositary Shares<BR>
Units </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Celldex Therapeutics, Inc. may offer, issue and sell from time
to time, together or separately, in one or more offerings, any combination of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&#8226;</TD><TD STYLE="text-align: justify">our common stock,</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">&#8226;</TD><TD STYLE="text-align: justify">our preferred stock, which we may issue in one or more
series,</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">&#8226;</TD><TD STYLE="text-align: justify">warrants,</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">&#8226;</TD><TD STYLE="text-align: justify">depositary shares, and</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">&#8226;</TD><TD STYLE="text-align: justify">units,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">up to a maximum aggregate offering price of $150,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> This prospectus provides a general description of the securities
we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus
(which includes an at-the-market offering prospectus). The prospectus supplement may also add, update or change information contained
in this prospectus. You should read this prospectus and the accompanying prospectus supplement, as well as the documents incorporated
or deemed incorporated by reference in this prospectus, carefully before you make your investment decision. Our common stock is
traded on the Nasdaq Capital Market under the symbol &quot;CLDX.&quot; On June 10, 2020, the last reported sale price of our
common stock on the Nasdaq Capital Market was $4.80 per share. You are urged to obtain current market quotations of the common
stock. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus may not be used to sell securities unless accompanied
by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer to sell these securities on a continuous or delayed
basis, through agents, dealers or underwriters, or directly to purchasers. The prospectus supplement for each offering of securities
will describe in detail the plan of distribution for that offering. If our agents or any dealers or underwriters are involved in
the sale of the securities, the applicable prospectus supplement will set forth the names of the agents, dealers or underwriters
and any applicable commissions or discounts. Our net proceeds from the sale of securities will also be set forth in the applicable
prospectus supplement. For general information about the distribution of securities offered, please see &quot;Plan of Distribution&quot;
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Investing in our securities involves risks. Before making
an investment decisions, you should carefully review the information contained in this prospectus under the heading &quot;Risk
Factors&quot; beginning on page 4 of this prospectus.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION OR REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL
OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is , 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="z_001"></A>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: right"></TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#a_001">1</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#a_002">PROSPECTUS SUMMARY</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#a_002">2</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#a_003">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#a_003">4</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#a_004">RISK FACTORS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#a_004">4</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#a_005">USE OF PROCEEDS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#a_005">4</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#a_006">DESCRIPTIONS OF SECURITIES WE MAY OFFER</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#a_006">5</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#a_007">DESCRIPTION OF COMMON STOCK</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#a_007">5</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#b_001">DESCRIPTION OF PREFERRED STOCK</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#b_001">6</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#b_002">DESCRIPTION OF WARRANTS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#b_002">9</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#b_003">DESCRIPTION OF DEPOSITARY SHARES</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#b_003">11</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#b_004">DESCRIPTION OF UNITS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#b_004">11</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#b_005">PLAN OF DISTRIBUTION</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#b_005">12</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#b_006">LEGAL MATTERS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#b_006">13</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#c_001">EXPERTS</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#c_001">14</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#c_002">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#c_002">14</A></TD></TR>
<TR STYLE="background-color: White">
<TD STYLE="text-indent: 0; padding-left: 0; vertical-align: top"><A HREF="#c_003">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></TD>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#c_003">14</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is a part of a registration statement that we
filed with the Securities and Exchange Commission, or the SEC, utilizing a &quot;shelf&quot; registration process. Under this shelf
registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or
more offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The registration statement containing this prospectus, including
the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus.
You should read the registration statement and the accompanying exhibits for further information. The registration statement, including
the exhibits and the documents incorporated or deemed incorporated herein by reference, can be read and are available to the public
over the Internet at the SEC's website at <I>http://www.sec.gov</I> as described under the heading &quot;Where You Can Find More
Information.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus provides you with a general description of the
securities we may offer. Each time we sell securities pursuant to this prospectus, we will provide a prospectus supplement (which
term includes, as applicable, the at-the-market offering prospectus filed with the registration statement of which this prospectus
forms a part) containing specific information about the terms of a particular offering by us. That prospectus supplement may include
a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may
add, update or change information in this prospectus. If the information in the prospectus is inconsistent with a prospectus supplement,
you should rely on the information in that prospectus supplement. You should read both this prospectus and, if applicable, any
prospectus supplement. See &quot;Where You Can Find More Information&quot; for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information incorporated by reference
or provided in this prospectus or any prospectus supplement. We have not authorized any dealer, salesman or other person to give
any information or to make any representation other than those contained or incorporated by reference in this prospectus or any
prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this
prospectus or any prospectus supplement. This prospectus and any prospectus supplement do not constitute an offer to sell or the
solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus
and any prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction
to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information
contained in this prospectus or any prospectus supplement is accurate on any date subsequent to the date set forth on the front
of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the
document incorporated by reference, even though this prospectus and any prospectus supplement is delivered or securities are sold
on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Unless this prospectus indicates otherwise or the context
otherwise requires, the terms &quot;we,&quot; &quot;our,&quot; &quot;us,&quot; &quot;Celldex&quot; or the &quot;Company&quot; as
used in this prospectus refer to Celldex Therapeutics, Inc. and its subsidiaries, except that such terms refer to only Celldex
Therapeutics, Inc. and not its subsidiaries in the sections entitled &quot;Description of Common Stock,&quot; &quot;Description
of Preferred Stock,&quot; &quot;Description of Warrants,&quot; &quot;Description of Depositary Shares,&quot; and &quot;Description
of Units.&quot;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"> We are a biopharmaceutical company focused
on the development and commercialization of immunotherapies and other targeted biologics. Our drug candidates are derived from
a broad set of human and bispecific antibodies which have the ability to engage the human immune system and/or directly inhibit
tumors to treat specific types of cancer or other diseases. They are aimed at addressing market opportunities for which we believe
current therapies are inadequate or non-existent. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are focusing our efforts and resources
on the continued research and development of: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8226;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> CDX-0159, a monoclonal antibody that specifically
        binds the KIT receptor and potently inhibits its activity, which recently completed a Phase 1a study in healthy volunteers
        where it demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, consistent
        with systemic mast cell suppression. We plan to study CDX-0159 in mast cell driven diseases, including, initially, chronic
        spontaneous urticaria (CSU) and chronic inducible urticarias (CINDUs); </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8226;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CDX-1140, an agonist
    monoclonal antibody targeted to CD40, a key activator of immune response, currently being studied as a single-agent and in
    combination with CDX-301, a dendritic cell growth factor. Dose escalation was recently completed in a Phase 1 study in solid
    tumors and lymphoma and the recommended dose for further study was determined to be 1.5 mg/kg, one of the highest systemic
    dose levels in the CD40 agonist class, for both CDX-1140 monotherapy and in combination with CDX-301. Celldex has initiated
    multiple expansion cohorts within the study, including a combination cohort with KEYTRUDA<SUP>&reg;</SUP>&nbsp;(pembrolizumab).
    The Company is exploring additional combination cohorts with mechanisms that we believe could be complementary or synergistic
    with CDX-1140;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8226;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CDX-3379, a monoclonal
    antibody designed to block the activity of ErbB3 (HER3), currently in an early Phase 2 study in advanced head and neck squamous
    cell cancer in combination with Erbitux<SUP>&reg;; </SUP>and</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8226;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> CDX-527, a bispecific antibody that uses our proprietary
        highly active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway,
        for which we are planning a Phase 1 study in advanced solid tumors. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We routinely work with external parties
to collaboratively advance our drug candidates. In addition to Celldex-led studies, we also have an Investigator Initiated Research
(IIR) program with multiple studies ongoing with our drug candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our goal is to build a fully integrated,
commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. We believe
our program assets provide us with the strategic options to either retain full economic rights to our innovative therapies or
seek favorable economic terms through advantageous commercial partnerships. This approach allows us to maximize the overall value
of our technology and product portfolio while best ensuring the expeditious development of each individual product. Currently,
all programs are fully owned by Celldex. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Corporate Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a Delaware corporation organized in 1983. Our principal
executive offices are located at Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827 and our telephone
number is (908) 200-7500. Our corporate website is www.celldex.com. The information on our website is not incorporated by reference
into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus, including the documents that we incorporate
by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements
about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may
be forward-looking. These statements are often, but not always, made through the use of words or phrases such as &quot;anticipate,&quot;
 &quot;estimate,&quot; &quot;plans,&quot; &quot;projects,&quot; &quot;continuing,&quot; &quot;ongoing,&quot; &quot;expects,&quot;
 &quot;management believes,&quot; &quot;we believe,&quot; &quot;we intend&quot; and similar words or phrases. Accordingly, these
statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed
in them. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in this prospectus
or discussed in documents incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements are subject to known and unknown
risks and uncertainties, which change over time, and are based on management's expectations and assumptions at the time the statements
are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated
in the forward-looking statements for many reasons including the factors described in the section entitled &quot;Risk Factors&quot;
in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date on which they were made. We undertake no obligation to publicly revise any forward-looking
statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events.
You should, however, review the factors and risks we describe in the reports we file from time to time with the SEC after the date
of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in this prospectus
at any time. All forward-looking statements are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>RISK FACTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Investing in our securities involves significant risks. Before
making an investment decision, you should carefully consider the risks and other information we include or incorporate by reference
in this prospectus and any prospectus supplement. In particular, you should consider the risk factors under the heading &quot;Risk
Factors&quot; included in our most recent Annual Report on Form 10-K, as may be revised or supplemented by our subsequent Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K, each of which are on file with the SEC and are incorporated herein by reference,
and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The
risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not currently
known to us or that we currently deem immaterial may also affect our business operations. Additional risk factors may be included
in a prospectus supplement relating to a particular offering of securities. Our business, financial condition or results of operations
could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these
risks, and you may lose all or part of your investment. This prospectus is qualified in its entirety by these risk factors.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise provided in the applicable prospectus supplement
to this prospectus used to offer specific securities, we expect to use the net proceeds from any offering of securities by us for
general corporate purposes, which may include acquisitions, capital expenditures, investments, payment of milestone payments, and
the repayment, redemption or refinancing of all or a portion of any indebtedness or other securities outstanding at a particular
time, to fund our operations until we receive FDA approval of our products and are able to commercialize our products and to make</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">substantial investments to establish sales, marketing, quality
control, and regulatory compliance capabilities in anticipation of FDA approval of our products. Pending the application of the
net proceeds, we expect to invest the net proceeds in short-term, interest-bearing instruments with a maturity of three months
or less at the date of purchase and consist primarily of investments in money market mutual funds with commercial banks and financial
institutions or other investment-grade securities. Such investments may include depositing such net proceeds into, and maintaining
cash balances with, financial institutions in excess of insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>DESCRIPTIONS OF SECURITIES WE MAY OFFER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus contains summary descriptions of the common
stock, preferred stock, warrants, depositary shares and units that we may offer and sell from time to time. The preferred stock
may also be exchangeable for and/or convertible into shares of common stock or another series of preferred stock. When one or more
of these securities are offered in the future, a prospectus supplement will explain the particular terms of the securities and
the extent to which these general provisions may apply. These summary descriptions and any summary descriptions in the applicable
prospectus supplement do not purport to be complete descriptions of the terms and conditions of each security and are qualified
in their entirety by reference to our third restated certificate of incorporation, as amended, our by-laws and by applicable Delaware
law and any other documents referenced in such summary descriptions and from which such summary descriptions are derived. If any
particular terms of a security described in the applicable prospectus supplement differ from any of the terms described herein,
then the terms described herein will be deemed superseded by the terms set forth in that prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue securities in book-entry form through one or more
depositaries, such as The Depository Trust Company, Euroclear or Clearstream, named in the applicable prospectus supplement. Each
sale of a security in book-entry form will settle in immediately available funds through the applicable depositary, unless otherwise
stated. We will issue the securities only in registered form, without coupons, although we may issue the securities in bearer form
if so specified in the applicable prospectus supplement. If any securities are to be listed or quoted on a securities exchange
or quotation system, the applicable prospectus supplement will say so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>DESCRIPTION OF COMMON STOCK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> As of June 10, 2020 we are authorized to issue up to
297,000,000 shares of common stock, $0.001 par value per share. As of June 10, 2020, approximately 20,675,269 shares of common
stock were outstanding. All outstanding shares of our common stock are fully paid and non-assessable. Our common stock is
listed on the Nasdaq Capital Market under the symbol &quot;CLDX&quot;. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 10pt"><I>Dividends</I></TD><TD></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors may, out of funds legally available,
at any regular or special meeting, declare dividends to the holders of shares of our common stock as and when they deem expedient,
subject to the rights of holders of the preferred stock, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 10pt"><I>Voting</I></TD><TD></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each share of common stock entitles the holders to one vote
per share on all matters requiring a vote of the stockholders, including the election of directors. No holders of shares of common
stock shall have the right to vote such shares cumulatively in any election for the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-indent: -10pt"><I>Rights Upon Liquidation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of our voluntary or involuntary liquidation, dissolution,
or winding up, the holders of our common stock will be entitled to share equally in our assets available for distribution after
payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in
full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 10pt"><I>Miscellaneous</I></TD><TD></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No holders of shares of our common stock shall have any preemptive
rights to subscribe for, purchase or receive any shares of any class, whether now or hereafter authorized, or any options or warrants
to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be issued,
sold or offered for sale by Celldex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-indent: -10pt"><I>Anti-Takeover Provisions </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain provisions in our third restated certificate of incorporation,
as amended, and applicable Delaware corporate, as well as our shareholder rights agreement, may have the effect of discouraging
a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders
receiving a substantial premium over the current market price of our shares. The primary purpose of these provisions is to encourage
negotiations with our management by persons interested in acquiring control of our corporation. These provisions may also tend
to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to
elect even a single director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Computershare Trust Company, N.A. is presently the transfer
agent and registrar for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_001"></A><B>DESCRIPTION OF PREFERRED STOCK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> At June 10, 2020, the Company had authorized preferred
stock comprised of 3,000,000 shares of Class C Preferred Stock of which 350,000 shares has been designated as Class C-1
Junior Participating Cumulative Preferred Stock, the terms of which are to be determined by our Board of Directors. As of
June 10, 2020, there was no preferred stock outstanding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Class C Preferred Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This section describes the general terms and provisions of
our Class C Preferred Stock. The applicable prospectus supplement will describe the specific terms of the shares of preferred
stock offered through that prospectus supplement, as well as any general terms described in this section that will not apply to
those shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors has been authorized to provide for the
issuance of the 2,650,000 unissued and undesignated shares of our Class C Preferred Stock In general, our third restated certificate
of incorporation, as amended, authorizes our board of directors to issue new shares of our common stock or preferred stock without
further stockholder action, provided that there are sufficient authorized shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With respect to each series of our Class C Preferred Stock,
our board of directors has the authority to fix the following terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">the designation of the series;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">the number of shares within the series;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD>whether dividends are cumulative and, if cumulative, the dates from which dividends are cumulative;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the rate of any dividends, any conditions upon which dividends are payable, and the dates of payment of dividends;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under
 &quot;Description of Depositary Shares&quot;;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>whether the shares are redeemable, the redemption price and the terms of redemption;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the amount payable to you for each share you own if we dissolve or liquidate;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>whether the shares are convertible or exchangeable, the price or rate of conversion or exchange, and the applicable terms and
conditions;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>any restrictions on issuance of shares in the same series or any other series;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>voting rights applicable to the series of preferred stock; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>any other rights, priorities, preferences, restrictions or limitations of such series.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights with respect to any shares of our Class C Preferred
Stock will be subordinate to the rights of our general creditors. Shares of our Class C Preferred Stock that we issue in accordance
with their terms will be fully paid and nonassessable, and will not be entitled to preemptive rights unless specified in the applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to issue preferred stock, or rights to purchase
such shares, could discourage an unsolicited acquisition proposal. For example, we could impede a business combination by issuing
a series of preferred stock containing class voting rights that would enable the holders of such preferred stock to block a business
combination transaction. Alternatively, we could facilitate a business combination transaction by issuing a series of preferred
stock having sufficient voting rights to provide a required percentage vote of the stockholders. Additionally, under certain circumstances,
our issuance of preferred stock could adversely affect the voting power of the holders of our common stock. Although our board
of directors is required to make any determination to issue any preferred stock based on its judgment as to the best interests
of our stockholders, our board of directors could act in a manner that would discourage an acquisition attempt or other transaction
that some, or a majority, of our stockholders might believe to be in their best interests or in which stockholders might receive
a premium for their stock over prevailing market prices of such stock. Our board of directors does not at present intend to seek
stockholder approval prior to any issuance of currently authorized stock, unless otherwise required by law or applicable stock
exchange requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Terms of the Preferred Stock
That We May Offer and Sell to You </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We summarize below some of the provisions that will apply to
the preferred stock that we may offer to you unless the applicable prospectus supplement provides otherwise. This summary may
not contain all information that is important to you. You should read the prospectus supplement, which will contain additional
information and which may update or change some of the information below. Prior to the issuance of a new series of preferred stock,
we will further amend our third restated certificate of incorporation, as amended, designating the stock of that series and the
terms of that series. We will file a copy of the certificate of designation that contains the terms of each new series of preferred
stock with the SEC each time we issue a new series of preferred stock. Each certificate of designation will establish the number
of shares included in a designated series and fix the designation, powers, privileges, preferences and rights of the shares of
each series as well as any applicable qualifications, limitations or restrictions. You should refer to the applicable certificate
of designation as well as our</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">third restated certificate of incorporation, as amended, before
deciding to buy shares of our preferred stock as described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors has the authority, without further action
by the stockholders, to issue preferred stock in one or more series and to fix the number of shares, dividend rights, conversion
rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any other rights, preferences, privileges
and restrictions applicable to each such series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of any preferred stock could adversely affect
the rights of the holders of common stock and, therefore, reduce the value of the common stock. The ability of our board of directors
to issue preferred stock could discourage, delay or prevent a takeover or other corporate action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of any particular series of preferred stock will
be described in the prospectus supplement relating to that particular series of preferred stock, including, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD>the designation, stated value and liquidation preference of such preferred stock;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the number of shares within the series;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the offering price;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and whether such dividends
shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under
 &quot;Description of Depositary Shares&quot;);</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>any redemption or sinking fund provisions;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the amount that shares of such series shall be entitled to receive in the event of our liquidation, dissolution or winding-up;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the terms and conditions, if any, on which shares of such series shall be convertible or exchangeable for shares of our stock
of any other class or classes, or other series of the same class;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the voting rights, if any, of shares of such series; the status as to reissuance or sale of shares of such series redeemed, purchased
or otherwise reacquired, or surrendered to us on conversion or exchange;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the conditions and restrictions, if any, on the payment of dividends or on the making of other distributions on, or the purchase,
redemption or other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior
to the shares of such series as to dividends or upon liquidation;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the conditions and restrictions, if any, on the creation of indebtedness by us or by any subsidiary, or on the issuance of any
additional stock ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>any additional dividend, liquidation, redemption, sinking or retirement fund and other rights, preferences, privileges, limitations
and restrictions of such preferred stock.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The description of the terms of a particular series of preferred
stock in the applicable prospectus supplement will not be complete. You should refer to the applicable amendment to our third
restated certificate of incorporation, as amended, for complete information regarding a series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preferred stock will, when issued against payment of the
consideration payable therefor, be fully paid and nonassessable. Unless otherwise specified in the applicable prospectus supplement,
each</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">series of preferred stock will, upon issuance, rank senior
to the common stock and on a parity in all respects with each other outstanding series of preferred stock. The rights of the holders
of our preferred stock will be subordinate to that of our general creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_002"></A><B>DESCRIPTION OF WARRANTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We summarize below some of the provisions that will apply
to the warrants unless the applicable prospectus supplement provides otherwise. This summary may not contain all information
that is important to you. The complete terms of the warrants will be contained in the applicable warrant certificate and
warrant agreement. These documents have been or will be included or incorporated by reference as exhibits to the registration
statement of which this prospectus is a part. You should read the warrant certificate and the warrant agreement. You should
also read the prospectus supplement, which will contain additional information and which may update or change some of the
information below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 10pt"><B>General</B></TD><TD></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue, together with other securities or separately,
warrants to purchase common stock, preferred stock or other securities. We may issue the warrants under warrant agreements to
be entered into between us and a bank or trust company, as warrant agent, all as set forth in the applicable prospectus supplement.
The warrant agent would act solely as our agent in connection with the warrants of the series being offered and would not assume
any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The applicable prospectus supplement will describe the following
terms, where applicable, of warrants in respect of which this prospectus is being delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD>the title of the warrants;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the designation, amount and terms of the securities for which the warrants are exercisable and the procedures and conditions relating
to the exercise of such warrants;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of warrants
issued with each such security;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the price or prices at which the warrants will be issued;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the aggregate number of warrants;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price
of the warrants;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the price or prices at which the securities purchasable upon exercise of the warrants may be purchased;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will be separately
transferable;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>if applicable, a discussion of the material U.S. federal income tax considerations applicable to the warrants;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the date on which the right to exercise the warrants shall commence and the date on which the right shall expire;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">if applicable, the maximum or minimum number of warrants which may be exercised at any time;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">the identity of the warrant agent;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">any mandatory or optional redemption provision;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">whether the warrants are to be issued in registered or bearer form;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">whether the warrants are extendible and the period or periods of such extendibility;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">information with respect to book-entry procedures, if any; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">any other terms of the warrants.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before exercising their warrants, holders of warrants will
not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends,
if any, or payments upon our liquidation, dissolution or winding-up or to exercise voting rights, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Exercise of Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant will entitle the holder thereof to purchase such
number of shares of common stock or preferred stock or other securities at the exercise price as will in each case be set forth
in, or be determinable as set forth in, the applicable prospectus supplement. Warrants may be exercised at any time up to the
close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the
expiration date, unexercised warrants will become void. Warrants may be exercised as set forth in the applicable prospectus supplement
relating to the warrants offered thereby. Upon receipt of payment and the warrant certificate properly completed and duly executed
at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will,
as soon as practicable, forward the purchased securities. If less than all of the warrants represented by the warrant certificate
are exercised, a new warrant certificate will be issued for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Enforceability of Rights of
Holders of Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant agent will act solely as our agent under the
applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any
warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will
have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any
duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a
warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate
legal action its right to exercise, and receive the securities purchasable upon exercise of, that holder's warrant(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B>Modification of the Warrant
Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrant agreement will permit us and the warrant agent,
without the consent of the warrant holders, to supplement or amend the agreement in the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD>to cure any ambiguity;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>to correct or supplement any provision which may be defective or inconsistent with any other provisions; or</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>to add new provisions regarding matters or questions that we and the warrant agent may deem necessary or desirable and which do
not adversely affect the interests of the warrant holders.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_003"></A><B>DESCRIPTION OF DEPOSITARY SHARES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We summarize below some of the provisions that will apply to
depositary shares unless the applicable prospectus supplement provides otherwise. This summary may not contain all information
that is important to you. The complete terms of the depositary shares will be contained in the depositary agreement and depositary
receipt applicable to any depositary shares. These documents have been or will be included or incorporated by reference as exhibits
to the registration statement of which this prospectus is a part. You should read the depositary agreement and the depositary
receipt. You should also read the prospectus supplement, which will contain additional information and which may update or change
some of the information below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 10pt"><B>General</B></TD><TD></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may, at our option, elect to offer fractional or multiple
shares of common stock or preferred stock, rather than single shares of common stock or preferred stock (to be set forth in the
prospectus supplement relating to such depositary shares). In the event we elect to do so, depositary receipts evidencing depositary
shares will be issued to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The shares of common stock or any class or series of preferred
stock represented by depositary shares will be deposited under a deposit agreement among us, a depositary selected by us, and
the holders of the depositary receipts. The depositary will be a bank or trust company having its principal office in the United
States and having a combined capital and surplus of at least $50,000,000. Subject to the terms of the deposit agreement, each
owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of common stock or preferred
stock represented by such depositary share, to all the rights and preferences of the shares of common stock or preferred stock
represented by the depositary share, including dividend, voting, redemption and liquidation rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The depositary shares will be evidenced by depositary receipts
issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the fractional shares
of common stock or the related class or series of preferred shares in accordance with the terms of the offering described in the
related prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_004"></A><B>DESCRIPTION OF UNITS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue units comprised of one or more of the other securities
described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of
each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included
security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held
or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD>the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances
those securities may be held or transferred separately;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>the terms of the unit agreement governing the units;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>United States federal income tax considerations relevant to the units; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD>whether the units will be issued in fully registered global form.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This summary of certain general terms of units and any summary
description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their entirety
by reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and depositary arrangements relating to such units. The forms
of the unit agreements and other documents relating to a particular issue of units will be filed with the SEC each time we issue
units, and you should read those documents for provisions that may be important to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_005"></A><B>PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities covered hereby from time to time
pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination
of these methods. A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative
securities, including without limitation, warrants and subscriptions. We may sell the securities to or through underwriters or
dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more
transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">at a fixed price or prices, which may be changed;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">at market prices prevailing at the time of sale;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">at prices related to such prevailing market prices;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">at varying prices determined at the time of sale; or</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">at negotiated prices.</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">A prospectus supplement or supplements will describe the terms of the offering of the securities, including:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 0.5in">&#8226;</TD>
    <TD>the name or names of the underwriters, dealers or agents participating in the offering, if any;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8226;</TD>
    <TD>the purchase price of the securities sold by us to any underwriter or dealer and the net proceeds we expect to receive from the
offering;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8226;</TD>
    <TD>any over-allotment options under which underwriters may purchase additional securities from us;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8226;</TD>
    <TD>any agency fees or underwriting discounts or commissions and other items constituting agents' or underwriters' compensation;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8226;</TD>
    <TD>any public offering price;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8226;</TD>
    <TD>any discounts or concessions allowed or reallowed or paid to dealers; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8226;</TD>
    <TD>any securities exchange or market on which the securities may be listed.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Only underwriters named in the prospectus supplement will be
underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If underwriters are used in the sale, they will acquire the
securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities
will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public
through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than
securities covered by any over-allotment option. Any public offering price and any discounts or commissions or concessions allowed
or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship.
We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell securities directly or through agents we designate
from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions
and other compensation we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise,
our agent will act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may authorize agents or underwriters to solicit offers by
certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will
describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may provide agents and underwriters with indemnification
against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect
to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in
transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All securities we may offer, other than common stock, will
be new issues of securities with no established trading market. Any agents or underwriters may make a market in these securities,
but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity
of the trading markets for any securities. There is currently no market for any of the offered securities, other than our common
stock which is listed on the Nasdaq Capital Market. We have no current plans for listing of the preferred stock, warrants or subscription
rights on any securities exchange or quotation system; any such listing with respect to any particular preferred stock, warrants
or subscription rights will be described in the applicable prospectus supplement or other offering materials, as the case may
be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any underwriter may engage in overallotment, stabilizing transactions,
short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales
in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the
securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters
to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing
or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it
would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any agents and underwriters who are qualified market makers
on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital Market in
accordance with Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers
or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified
as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent
bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's
bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_006"></A><B>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated in the applicable prospectus supplement,
the validity of the securities offered hereby will be passed upon for us by Lowenstein Sandler LLP, New York, New York. If the
validity of the securities offered hereby in connection with offerings made pursuant to this prospectus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">are passed upon by counsel for the underwriters, dealers or
agents, if any, such counsel will be named in the prospectus supplement relating to such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c_001"></A>EXPERTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The financial statements incorporated in this Prospectus
by reference to the Annual Report on Form 10-K for the year ended December 31, 2019 have been so incorporated in reliance on the
report (which contains an explanatory paragraph relating to the Company&rsquo;s ability to continue as a going concern as described
in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c_002"></A>WHERE YOU CAN FIND MORE INFORMATION
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have filed with the SEC a registration statement on Form
S-3, including exhibits, under the Securities Act of which this prospectus forms a part. This prospectus does not contain all of
the information set forth in the registration statement. This prospectus contains descriptions of certain agreements or documents
that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions
and are not necessarily complete, and each statement is qualified in all respects by reference to such agreement or document. For
further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We file annual, quarterly and current reports, proxy statements
and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at <I>http://www.sec.gov</I>.
The SEC's website contains reports, proxy statements and other information regarding issuers, such as Celldex Therapeutics, Inc.,
that file electronically with the SEC. We make available free of charge through our web site our Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements on Schedule 14A and all amendments to those reports as soon
as reasonably practicable after such material is electronically filed with or furnished to the SEC. Our website address is <I>http://www.celldextherapeutics.com</I>.
Please note that our website address is provided as an inactive textual reference only. Information contained on or accessible
through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference
unless such information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c_003"></A>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to &quot;incorporate by reference&quot; into
this prospectus the information we have filed with the SEC, which means that we can disclose important information to you by referring
you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate
by reference into this prospectus the information contained in the documents listed below, which is considered to be a part of
this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt; width: 1in">&#8226;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920001809/a2241053z10-k.htm" STYLE="-sec-extract: exhibit">Our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 26, 2020;</A></FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt"> &#8226; </TD>
    <TD> Our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465920057436/tm2014426-1_10q.htm" STYLE="-sec-extract: exhibit">May 6, 2020</A>; </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&#8226;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920002644/a2241464zdef14a.htm" STYLE="-sec-extract: exhibit">Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2020 (other than the portions thereof which are furnished and not filed);</A> and</FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-left: 10pt"> &#8226; </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The description of our common stock contained in our Registration Statement
on Form 8-A, filed on </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746904033435/a2146123z8-a12g.htm" STYLE="-sec-extract: exhibit">November 8, 2004,</A> as amended by Form 8-A/A filed on <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465907076169/a07-27173_78a12ga.htm" STYLE="-sec-extract: exhibit">October 22, 2007</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016208/a08-7663_18a12ga.htm" STYLE="-sec-extract: exhibit">March 7, 2008</A>.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also incorporate by reference all documents we file under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (a) after the initial filing date of the registration statement of which
this prospectus is a part and before the effectiveness of the registration statement and (b) after the effectiveness of the registration
statement and before the filing of a post-effective amendment that indicates that the securities offered by this prospectus have
been sold or that deregisters the securities covered by this prospectus then remaining unsold. The most recent information that
we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will
be deemed to be a part of this prospectus, commencing on the date on which the document is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nothing in this prospectus shall be deemed to incorporate information
furnished but not filed with the SEC pursuant to Item 2.02 or 7.01 of Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will furnish without charge to each person, including any
beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by reference
other than exhibits to those documents. Requests should be addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Corporate Secretary<BR>
Celldex Therapeutics, Inc.<BR>
Perryville III Building, 53 Frontage Road, Suite 220,<BR>
Hampton, New Jersey 08827<BR>
(908) 200-7500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="tm2022403-1_s3aimg01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>$150,000,000<BR>
Common Stock<BR>
Preferred Stock<BR>
Warrants</B></FONT><B><BR>
</B></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Depositary
Shares<BR>
Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>, 2020 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II<BR>
<BR>
INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Other Expenses of Issuance and Distribution. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated costs and expenses
payable by the Registrant in connection with the registration of the securities being registered under this Registration Statement.
All amounts shown are estimates except the Securities and Exchange Commission registration statement filing fee and the FINRA fee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt; width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Statement filing fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,470</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These fees are calculated on the securities offered and the
number of issuances and accordingly cannot be estimated at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15. Indemnification of Directors and Officers. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Celldex is a Delaware corporation. In accordance with the Delaware
General Corporation Law (the &quot;DGCL&quot;), Article Six of the Registrant's Third Restated Certificate of Incorporation, as
amended, provides that no director of the Registrant shall be personally liable to the Registrant or its stockholders for breach
of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to Celldex or its stockholders,
(ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under
Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The DGCL permits, but does not require, a corporation to
indemnify its directors, officers, employees or agents and expressly provides that the indemnification provided for under the
DGCL shall not be deemed exclusive of any indemnification right under any bylaw, agreement, vote of stockholders or
disinterested directors, or otherwise. The DGCL permits indemnification against expenses and certain other liabilities
arising out of legal actions brought or threatened against such persons for their conduct on behalf of the corporation,
provided that each such person acted in good faith and in a manner that he or she reasonably believed was in or not opposed
to the corporation's best interests and in the case of a criminal proceeding, had no reasonable cause to believe his or her
conduct was unlawful. The DGCL does not allow indemnification of directors in the case of an action by or in the right of the
corporation (including stockholder derivative suits) unless the directors successfully defend the action or indemnification
is ordered by the court. The Amended and Restated Bylaws of Celldex (the &quot;Bylaws&quot;) provide for indemnification to
the directors, officers, employees and agents of Celldex consistent with that authorized by the DGCL. Insofar as
indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors and
officers of Celldex pursuant to the foregoing provision or otherwise, Celldex has been advised that, in the opinion of the
Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Exchange Act
of 1934, as amended, and is therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Celldex currently carries a directors' and officers' liability
insurance policy which provides for payment of expenses of Celldex's directors and officers in connection with threatened, pending
or completed actions, suits or proceedings against them in their capacities as directors and officers, in accordance with the Bylaws
and the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee"></P>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
<TD STYLE="text-align: right; width: 4%; vertical-align: top">&nbsp;</TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="width: 47%">&nbsp;</TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: black 1pt solid; vertical-align: top; padding-bottom: 0.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>No. </B></FONT></TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description </B></FONT></TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Location </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.1</FONT></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Underwriting Agreement</FONT></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To be filed, if applicable, by amendment or by a report filed under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, and incorporated herein by reference.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465916153723/a16-20866_1ex2d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.1</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465916153723/a16-20866_1ex2d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Agreement and Plan of Merger, dated as of November 1, 2016, by and among Kolltan Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Connemara Merger Sub 1 Inc. and Connemara Merger Sub 2 LLC</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465916153723/a16-20866_1ex2d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 2.1 of Celldex's Current Report on Form 8-K, filed November 1, 2016.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Third Restated Certificate of Incorporation of Celldex</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.1 of Celldex's Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.2</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.1 of Celldex's Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.3</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Second Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/0001029869-98-000936-index.html" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.2 of Celldex's Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465902001892/j3484_ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.4</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465902001892/j3484_ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Third Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465902001892/j3484_ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.1 of Celldex's Quarterly Report on Form 10-Q, filed May 10, 2002.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746908003032/a2183530zex-3_5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.5</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746908003032/a2183530zex-3_5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended and Restated By-Laws of Celldex as of March 14, 2007</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746908003032/a2183530zex-3_5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.5 of Celldex's Annual Report on Form 10-K, filed March 18, 2008.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746904033435/a2146123zex-3_1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.6</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746904033435/a2146123zex-3_1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of Celldex classifying and designating the Series C-1 Junior Participating Cumulative Preferred Stock</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746904033435/a2146123zex-3_1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.1 of Celldex's Registration Statement on Form 8-A, filed November 8, 2004.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746905006822/a2153359zex-3_6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.7</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746905006822/a2153359zex-3_6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Elimination of Series C-1 Junior Participating Cumulative Preferred Stock</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746905006822/a2153359zex-3_6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.6 of Celldex's Annual Report on Form 10-K, filed March 16, 2005.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016816/a08-7923_1ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.8</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016816/a08-7923_1ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Fourth Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016816/a08-7923_1ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.1 of Celldex's Current Report on Form 8-K, filed on March 11, 2008.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016816/a08-7923_1ex3d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.9</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016816/a08-7923_1ex3d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Fifth Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016816/a08-7923_1ex3d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.2 of Celldex's Current Report on Form 8-K, filed on March 11, 2008.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908069812/a08-25757_1ex3d7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.10</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908069812/a08-25757_1ex3d7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Sixth Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908069812/a08-25757_1ex3d7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.7 of Celldex's Quarterly Report on Form 10-Q, filed on November 10, 2008.</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; padding-bottom: 0.5pt; font-size: 10pt; text-align: right; width: 4%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.
    </B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt; text-align: center; width: 47%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    </B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt; text-align: center; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Location
    </B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465914026295/a14-10147_1ex3d1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465914026295/a14-10147_1ex3d1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated
    By-Laws, dated April 7, 2014</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465914026295/a14-10147_1ex3d1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 3.1 of Celldex's Current Report on Form 8-K, filed on April 8, 2014.</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465919006667/a19-4170_1ex3d1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">4.12</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465919006667/a19-4170_1ex3d1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Seventh Certificate of Amendment of Third Restated Certificate
    of Incorporation</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465919006667/a19-4170_1ex3d1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.1 of Celldex's Current
    Report on Form 8-K, filed on February 8, 2019.</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465919006667/a19-4170_1ex4d1.htm"> <FONT STYLE="font-size: 10pt">4.13</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465919006667/a19-4170_1ex4d1.htm"> <FONT STYLE="font-size: 10pt">Specimen of Common Stock Certificate</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465919006667/a19-4170_1ex4d1.htm"> <FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 4.1 of Celldex's Current
    Report on Form 8-K, filed on February 8, 2019.</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">4.14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Form of Warrant Agreement</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">To be filed subsequently by an amendment to the Registration
    Statement or by a Current Report of the Registrant on a Current Report on Form 8-K and incorporated by reference therein.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">4.15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Form of Warrant Certificate</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Included in Exhibit 4.14.</FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">4.16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Specimen of Preferred Stock Certificate</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">To be filed subsequently by an amendment to the Registration
    Statement or by a Current Report of the Registrant on a Current Report on Form 8-K and incorporated by reference therein.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">4.17</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Form of Depositary Agreement</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">To be filed subsequently by an amendment to the Registration
    Statement or by a Current Report of the Registrant on a Current Report on Form 8-K and incorporated by reference therein.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">4.18</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Form of Depositary Receipt</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Included in Exhibit 4.17.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">4.19</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Form of Unit Agreement</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">To be filed subsequently by an amendment to the Registration
    Statement or by a Current Report of the Registrant on a Current Report on Form 8-K and incorporated by reference therein.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">5.1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Opinion of Lowenstein Sandler LLP as to the legality of the securities
    being registered</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Previously filed.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><A HREF="tm2022403d1_ex23-1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">23.1</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2022403d1_ex23-1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Consent of PricewaterhouseCoopers LLP, Independent Registered
    Public Accounting Firm</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2022403d1_ex23-1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Filed herewith.</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">23.2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Consent of Lowenstein Sandler LLP</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Included in Exhibit 5.1.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">24.1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Powers of Attorney</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">Previously filed.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To file, during any period in which offers or
sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 0.5in">(i)</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">To include any prospectus required by Section 10(a)(3) of the Securities Act;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(ii)</TD>
    <TD>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering
price set forth in the &quot;Calculation of Registration Fee&quot; table in the effective registration statement; and</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(iii)</TD>
    <TD>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>provided,
however</I></FONT>, Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement
is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities
Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus
filed pursuant to Rule 424(b) that is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(2) </TD>
    <TD>That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial <I>bona fide</I> offering thereof.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(3)</TD>
    <TD>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(4)</TD>
    <TD>That, for the purpose of determining liability under the Securities Act to any purchaser, (A) each prospectus filed by the registrant
pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed
part of and included in the registration statement; and (B) each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5),
or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i),
(vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed
to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after
effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided
in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed
to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
Provided, however, that no statement made in a registration statement or</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD>prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into
the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document immediately prior to such effective date.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(5)</TD>
    <TD>That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(i)</TD>
    <TD>Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 102pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(ii)</TD>
    <TD>Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 102pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(iii)</TD>
    <TD>The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 102pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(iv)</TD>
    <TD>Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 102pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">(b) </TD>
    <TD>The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
of the registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of
an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.75in">(c)</TD>
    <TD STYLE="text-align: left">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed
by the final adjudication of such issue.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#z_001"><FONT STYLE="font-size: 10pt">Table of Contents</FONT></A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000ee">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Pursuant to the requirements of the Securities Act, the
Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Hampton, State of New Jersey, on June 11, 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CELLDEX THERAPEUTICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; width: 53%">&nbsp;</TD>
<TD STYLE="vertical-align: top; font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 44%">/s/ ANTHONY S. MARUCCI</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">Anthony S. Marucci</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom"><I>President and Chief Executive Officer</I></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933,
as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 31%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature
    </B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; width: 34%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    </B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; width: 31%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    </B></FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    ANTHONY S. MARUCCI</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD ROWSPAN="2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer
    and Director (Principal Executive Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 11,
    2020</FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony S. Marucci</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    SAM MARTIN</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD ROWSPAN="2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President, Chief
    Financial Officer and Treasurer (Principal Financial and Accounting Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 11,
    2020</FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sam Martin</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD ROWSPAN="2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chair of the Board
    of Directors</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Karen L. Shoos</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 11,
    2020</FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD ROWSPAN="2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keith L. Brownlie</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 11,
    2020</FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD ROWSPAN="2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Herbert J. Conrad</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 11,
    2020</FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD ROWSPAN="2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James J. Marino</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 11,
    2020</FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD ROWSPAN="2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harry H. Penner,
    Jr.</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 11,
    2020</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 6%"> *By: &nbsp; </TD>
<TD STYLE="width: 43%; border-bottom: Black 1pt solid; padding-left: 10pt; font-size: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Sam Martin</FONT>&nbsp; </TD>
<TD STYLE="width: 51%"> &nbsp; &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> Name: &nbsp; </TD>
<TD> Sam Martin &nbsp; </TD>
<TD> &nbsp; &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> Title: &nbsp; </TD>
<TD> Attorney-in-fact &nbsp; </TD>
<TD> &nbsp; &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>tm2022403d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We hereby consent to the incorporation by reference in this
Amendment No.1 to the Registration Statement on Form&nbsp;S-3/A of Celldex Therapeutics, Inc. of our report dated March 26, 2020
relating to the financial statements, which appears in Celldex Therapeutics Inc.&rsquo;s Annual Report on Form 10-K for the year ended
December&nbsp;31, 2019. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> /s/ PricewaterhouseCoopers LLP<BR>
Boston, Massachusetts </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> June 11, 2020 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2022403-1_s3aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2022403-1_s3aimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% .0# 2(  A$! Q$!_\0
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9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2022403-1_s3aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2022403-1_s3aimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' 0$# 2(  A$! Q$!_\0
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M8]]X_P!2N]9M;Y4$,-JQ9;=3D,#P0Q[G'Y5XF.Q=.<[1.N$XX96F]7T/9RP
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M5_H_B/\ L[7;2*.W?/EW$.3D9X;![>OI7%?#;6]/'Q)U&WT5)(M+U"(R+#,
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MY+K-O=?#/XEIK<:2OH]]*Q8J,Y#<O']0?F7U [X->V65LEG8PVR8"Q($&!V
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
